Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ404,54050,25
KB492,5494,5-0,20
PKN61,1661,221,10
Msft-0,92
Nokia2,7542,77150,20
IBM-3,33
Daimler AG24,3424,36-2,60
PFE2,34
03.04.2020 22:51:29
Indexy online
AD Index online
select
AD Index online
 

  • 03.04.2020 17:35:27
Virbac SA (VIRB.PA, Paris)
Poslední obchod Změna (%) Změna (EUR) Objem obchodů (EUR)
165,20 -4,51 -7,80 673 237
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 03.04.2020
Popis společnosti
Obecné informace
Název společnostiVirbac SA
TickerVIRP
Kmenové akcie:Ordinary Shares
RICVIRB.PA
ISINFR0000031577
Poslední známé roční výsledky31.12.2019
Poslední známé čtvrtletní výsledky31.12.2019
Počet zaměstnanců k 31.12.2018 4 893
Akcie v oběhu k 31.12.2019 8 431 822
MěnaEUR
Kontaktní informace
Ulice13eme rue LID, Bp 27, Carros Cedex
MěstoCARROS
PSČ06510
ZeměFrance
Kontatní osoba 
Funkce kontaktní osoby 
Telefon33 492 087 100
Fax33492087165

Business Summary: Virbac SA is a France-based veterinarian pharmaceutical company that specializes in the development and production of vaccines and medicines for domestic animals and livestock. Its production centers are located in France, Australia, the United States, Mexico, Vietnam, Brazil and South Africa. Its development efforts focus mainly on formulating drugs designed to prevent or cure certain animal diseases. Its product portfolio encompasses pet medications such as pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds and rodents, as well as livestock medications including pest control drugs and antibiotics intended for cattle, sheep, pigs and poultry. It also offers food and electronic identification chips for pets.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2019, Virbac SA revenues increased 8% to EUR938.3M. Net income increased from EUR20.1M to EUR51.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Income from disposals of assets increase from EUR387K to EUR7.3M (income), Foreign exchange gains and losses decrease of 27% to EUR7.3M (expense).
Odvětvová klasifikace
TRBC2012Veterinary Drugs
RBSS2004Pharmaceuticals - Generic & Specialty
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSBiological Product (except Diagnostic) Manufacturing
SICPharmaceutical Preparations
SICBiological Prod's Not Diagnostic



  • Poslední aktualizace: 03.04.2020
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairwoman of the Supervisory BoardMarie-Helene Dick54
Chairman of the Management BoardSebastien Huron4820.12.201721.12.2012
Chief Executive Officer, Director of Development, Member of the Management BoardChristian Karst60
Vice Chairman of the Supervisory BoardPierre Madelpuech5805.09.2017
Chief Financial Officer, Member of the Management BoardHabib Ramdani4301.01.2016
Head of Special Projects, Member of the Management BoardJean-Pierre Dick53